Intas Pharmaceuticals Reports Real-World Study Results of Razumab (biosimilar, ranibizumab) for Polypoidal Choroidal Vasculopathy
Shots:
- The real-world study in India evaluating Razumab vs Lucentis, showed that Razumab had comparable visual acuity outcomes to Lucentis with an adequate safety profile, changes in BCVA, SRF, IRF, SRF height, SFCT & the safety profiles were assessed at 12/24/52wk.
- Improvement from baseline in BCVA was significant in the reference product at all visits (12/24/52wk.) with a greater mean no. of inj. whereas improvement did not reach statistical significance in the biosimilar group until 52wks.
- SRF height & proportions of eyes with SRF was similar b/w groups at baseline and all visits with no significant changes in SFCT and the proportion of eyes with IRF & SRF in either group but reduction in SRF height in both groups at 52wk., reference product had less SFCT over biosimilar at 52wk. no other ocular or systemic adverse effects were observed
Ref: The Center For Biosimilar | Image: Intas
Related News:- Intas Reports Results of Razumab (biosimilar, ranibizumab) in the Real-world Study for the Treatment of Diabetic Macular Edema in India
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
